Drug Target Review2023-11-21T12:00:58
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-09-01T07:00:00Z
Sponsored by Promega Corporation
2026-11-11T14:00:00Z
Sponsored by Cell Signaling Technology
2026-06-09T08:20:00
Contributor Steve Smith, Drug Target Review
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2023-03-20T13:41:33
Sponsored by Bio-Techne
2024-01-26T13:22:42
Sponsored by bit.bio
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, Drug Target Review
Site powered by Webvision Cloud